Immunological Pattern in IgA Nephropathy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Feb 23

PMID 32085673

Citations 17

Authors

Clara Esteve Cols

Freddzia-Amanda Graterol Torres

Bibiana Quirant Sanchez

Helena Marco Rusinol

Maruja Isabel Navarro Diaz

Jordi Ara Del Rey

Eva Ma Martinez Caceres

Affiliations

Soon will be listed here.

Abstract

The current gold-standard diagnostic technique for IgA nephropathy (IgAN), the leading form of primary glomerulonephritis, is renal biopsy. CD89 (the main IgA receptor) is expressed on the surface of monocytes and plays a role in disease pathogenesis. Immunocomplexes formed by sCD89 (soluble form) and Gd-IgA1 are related to disease prognosis. We hypothesize that reduced CD89 surface expression on monocytes may be a marker of disease severity. We aimed to analyze leukocyte subpopulations in peripheral blood and CD89 surface expression on monocytes in a prospective study of 22 patients and 12 healthy subjects (HS). Leukocyte subpopulations and CD89 expression were analyzed by flow cytometry. IgAN patients had a higher percentage of activated and effector memory CD4 and CD8 T lymphocytes, a lower percentage of transitional B lymphocytes and plasmablasts, and a higher percentage of CD56CD16 NK cells and myeloid dendritic cells compared with HS. Correlations between reduced CD89 expression levels on nonclassical monocytes, histological findings of a poor prognosis on renal biopsy and baseline renal function were observed. IgAN patients show a characteristic immunological pattern in peripheral blood. A reduced expression level of CD89 on nonclassical monocytes identifies patients with a worse renal prognosis.

Citing Articles

Exploring the causal association between circulating leukocyte count and IgA nephropathy based on two-sample Mendelian randomization: possible role of transitional B cells.

Fang F, Wang H, Luo J, Hong F Clin Exp Nephrol. 2025; .

PMID: 40011364 DOI: 10.1007/s10157-025-02646-3.

Gene prediction of the causal relationship between immune cells and IgA nephropathy: A bidirectional Mendelian randomization study.

Zhang Y, Zhang C, Liu G, He P, Wan B Medicine (Baltimore). 2024; 103(46):e40480.

PMID: 39560595 PMC: 11575961. DOI: 10.1097/MD.0000000000040480.

Prognostic Value of Inflammation Scores and Hematological Indices in IgA and Membranous Nephropathies: An Exploratory Study.

Pana N, Stefan G, Popa T, Ciurea O, Stancu S, Capusa C Medicina (Kaunas). 2024; 60(8).

PMID: 39202473 PMC: 11356348. DOI: 10.3390/medicina60081191.

Causal role of immune cells in IgA nephropathy: a mendelian randomization study.

Shu J, Ge Y, Wu Y Ren Fail. 2024; 46(2):2381593.

PMID: 39039855 PMC: 11268262. DOI: 10.1080/0886022X.2024.2381593.

Cathepsin S (CTSS) in IgA nephropathy: an exploratory study on its role as a potential diagnostic biomarker and therapeutic target.

Fu S, Wu M, Cheng Y, Guan Y, Yu J, Wang X Front Immunol. 2024; 15:1390821.

PMID: 38979419 PMC: 11229174. DOI: 10.3389/fimmu.2024.1390821.

References

Quirant-Sanchez B, Hervas-Garcia J, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A . Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients. CNS Neurosci Ther. 2018; 24(12):1175-1184. PMC: 6489963. DOI: 10.1111/cns.12851. View

Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L . IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005; 67(2):504-13. DOI: 10.1111/j.1523-1755.2005.67107.x. View

Novak J, Julian B, Mestecky J, Renfrow M . Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol. 2012; 34(3):365-82. DOI: 10.1007/s00281-012-0306-z. View

Launay P, Grossetete B, Gaudin E, Torres S, Beaudoin L, Patey-Mariaud de Serre N . Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med. 2000; 191(11):1999-2009. PMC: 2213528. DOI: 10.1084/jem.191.11.1999. View

Cooper M, Fehniger T, Caligiuri M . The biology of human natural killer-cell subsets. Trends Immunol. 2001; 22(11):633-40. DOI: 10.1016/s1471-4906(01)02060-9. View

Boyette L, Macedo C, Hadi K, Elinoff B, Walters J, Ramaswami B . Phenotype, function, and differentiation potential of human monocyte subsets. PLoS One. 2017; 12(4):e0176460. PMC: 5406034. DOI: 10.1371/journal.pone.0176460. View

Cattran D, Coppo R, Cook H, Feehally J, Roberts I, Troyanov S . The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5):534-45. DOI: 10.1038/ki.2009.243. View

Segarra-Medrano A, Carnicer-Caceres C, Valtierra-Carmeno N, Agraz-Pamplona I, Ramos-Terrades N, Escalante E . Study of the variables associated with local complement activation in IgA nephropathy. Nefrologia. 2017; 37(3):320-329. DOI: 10.1016/j.nefro.2016.11.019. View

10.

Novak J, Vu H, Novak L, Julian B, Mestecky J, Tomana M . Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int. 2002; 62(2):465-75. DOI: 10.1046/j.1523-1755.2002.00477.x. View

11.

Boyd J, Cheung C, Molyneux K, Feehally J, Barratt J . An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012; 81(9):833-43. DOI: 10.1038/ki.2011.501. View

12.

Coppo R . Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol. 2016; 30(3):339-346. DOI: 10.1007/s40620-016-0360-z. View

13.

Monteiro R . Role of IgA and IgA fc receptors in inflammation. J Clin Immunol. 2009; 30(1):1-9. DOI: 10.1007/s10875-009-9338-0. View

14.

Cox S, Serino G, Sallustio F, Blasi A, Rossini M, Pesce F . Altered monocyte expression and expansion of non-classical monocyte subset in IgA nephropathy patients. Nephrol Dial Transplant. 2015; 30(7):1122-232. DOI: 10.1093/ndt/gfv017. View

15.

Barratt J, Feehally J . IgA nephropathy. J Am Soc Nephrol. 2005; 16(7):2088-97. DOI: 10.1681/ASN.2005020134. View

16.

Oortwijn B, Roos A, Royle L, van Gijlswijk-Janssen D, Faber-Krol M, Eijgenraam J . Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy. J Am Soc Nephrol. 2006; 17(12):3529-39. DOI: 10.1681/ASN.2006040388. View

17.

Robert T, Berthelot L, Cambier A, Rondeau E, Monteiro R . Molecular Insights into the Pathogenesis of IgA Nephropathy. Trends Mol Med. 2015; 21(12):762-775. DOI: 10.1016/j.molmed.2015.10.003. View

18.

Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y . Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015; 30(8):1315-21. PMC: 4513896. DOI: 10.1093/ndt/gfv221. View

19.

Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi A, Matsuoka K . A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One. 2014; 9(5):e98081. PMC: 4032235. DOI: 10.1371/journal.pone.0098081. View

20.

Gharavi A, Moldoveanu Z, Wyatt R, Barker C, Woodford S, Lifton R . Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008; 19(5):1008-14. PMC: 2386728. DOI: 10.1681/ASN.2007091052. View